Arcadia Wealth Management Inc. acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 19,850 shares of the biopharmaceutical company's stock, valued at approximately $527,000.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the 4th quarter valued at about $26,000. Clarity Asset Management Inc. purchased a new stake in Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC grew its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer in the 4th quarter valued at $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer during the 4th quarter worth $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Analyst Ratings Changes
PFE has been the subject of a number of research reports. Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $29.17.
Read Our Latest Report on PFE
Pfizer Price Performance
Shares of NYSE:PFE traded down $0.43 on Wednesday, hitting $23.18. The company had a trading volume of 36,659,825 shares, compared to its average volume of 41,097,811. The company has a market cap of $131.79 billion, a PE ratio of 16.44, a PEG ratio of 0.64 and a beta of 0.58. The business has a 50 day moving average of $23.28 and a 200 day moving average of $25.12. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period last year, the company earned $0.82 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.42%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also

Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.